This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Using their pooled, prospective multicenter registry of over 11,000 Korean stroke survivors, Dr. Kim et al. reported the estimated direct healthcare costs in the years after acute ischemic stroke. Unsurprisingly, the estimated direct costs of care (including costs of inpatient and outpatient visits, prescription medications, and long-term care) were significantly greater in the year after stroke than the year before (mean $38,152 USD vs $8,718 USD), with a 5-year cumulative poststroke cost estimated at $117,576 USD. Importantly, there was considerable variation in the 5-year cumulative healthcare costs based on 3-month disability using the modified Rankin Scale (mRS). Compared with patients with no disability (mRS 0), patients dependent on others for ambulation and for activities of daily living (mRS 4) incurred considerably greater costs over the same period ($279,188 vs $53,578). Because healthcare administrators and policy makers determine healthcare reimbursement rates for various conditions and treatments, it is critical that any independent benefit of acute stroke intervention (e.g., reperfusion therapies) be evaluated thoroughly—as pointed out by Drs. Ganesh and Varma. In this analysis, recanalization therapies were strongly associated with better 3-month functional outcomes but paradoxically increased inpatient and outpatient care costs in the final multivariable model. It seems that the long-term functional disability (3-month mRS) was the principal driver of the cost effect, and after adjustment for this variable, any cost savings from recanalization could be negated. To clarify whether (and to what degree) acute recanalization therapies may mediate the long-term cost savings in stroke survivors, the investigators are exploring ways to model this in a follow-up analysis.
Using their pooled, prospective multicenter registry of over 11,000 Korean stroke survivors, Dr. Kim et al. reported the estimated direct healthcare costs in the years after acute ischemic stroke. Unsurprisingly, the estimated direct costs of care (including costs of inpatient and outpatient visits, prescription medications, and long-term care) were significantly greater in the year after stroke than the year before (mean $38,152 USD vs $8,718 USD), with a 5-year cumulative poststroke cost estimated at $117,576 USD. Importantly, there was considerable variation in the 5-year cumulative healthcare costs based on 3-month disability using the modified Rankin Scale (mRS). Compared with patients with no disability (mRS 0), patients dependent on others for ambulation and for activities of daily living (mRS 4) incurred considerably greater costs over the same period ($279,188 vs $53,578). Because healthcare administrators and policy makers determine healthcare reimbursement rates for various conditions and treatments, it is critical that any independent benefit of acute stroke intervention (e.g., reperfusion therapies) be evaluated thoroughly—as pointed out by Drs. Ganesh and Varma. In this analysis, recanalization therapies were strongly associated with better 3-month functional outcomes but paradoxically increased inpatient and outpatient care costs in the final multivariable model. It seems that the long-term functional disability (3-month mRS) was the principal driver of the cost effect, and after adjustment for this variable, any cost savings from recanalization could be negated. To clarify whether (and to what degree) acute recanalization therapies may mediate the long-term cost savings in stroke survivors, the investigators are exploring ways to model this in a follow-up analysis.
Footnotes
Author disclosures are available upon request (journal{at}neurology.org).
- © 2021 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Alert Me
Recommended articles
Three-month modified Rankin Scale as a determinant of 5-year cumulative costs after ischemic stroke
Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke
Real-life costs and effects of an implementation program to increase thrombolysis in stroke
Cost-effectiveness of endovascular therapy for acute ischemic stroke